The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...
ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...
REMICADE® (INFLIXIMAB) RECEIVES POSITIVE OPINION FROM CHMP IN EUROPE FOR TREATMENT OF ULCERATIVE COLITIS IN PEDIATRIC PATIENTS Positive Opinion Recommends Approval of the First and Only Anti-TNF ...
Since the late 1990s, multiple biologic drugs have been approved to help people with ulcerative colitis (UC) and Crohn’s disease achieve and maintain remission. This includes biosimilars, which are ...
LAS VEGAS -- In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar CT-P13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results